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Human erythrocytes interact with particles or soluble immune complexes bearing 
C3b, the major fragment of the third component of complement. This phenomenon 
is known  as  immune  adherence  (1).  B  lymphocytes  (2),  neutrophils,  macrophages, 
monocytes (3-5), and epithelial cells of the kidney glomerulus (6) also have membrane 
receptors  for  C3b.  The  C3b  receptors  function  in  phagocytosis,  facilitating  the 
attachment of the particle to the phagocytes, and, in synergy with the Fc receptors for 
IgG,  promote  ingestion  of sensitized  particles  (7,  8).  Recently,  a  glycoprotein  of 
205,000  mol wt has been  isolated  from the  membrane  of human  erythrocytes  and 
identified  as the C3b  receptor  (CR1)  (9,  10).  This protein was characterized  as an 
inhibitor of the alternative pathway C3 convertase (C3b,Bb)  and as a cofactor for the 
cleavage  of the a'  chain  of C3b  in  the  fluid  phase  by  a  serum  enzyme,  C3b/C4b 
inactivator. 
Complement  receptors for C3b have also been reported to bind C4b  (11,  12).  For 
this  reason,  we  searched  for  evidence  of interactions  between  C4b  and  CR1  by 
studying  the  effects  of CR1  on  the  enzymes  of the  classical  complement  pathway 
whose  functions  are  C4b  dependent;  that  is,  C4b,2a  and  C4b,2a,3b  (C3  and  C5 
convertases). 
Materials and Methods 
Buffers.  Buffers used were:  isotonic veronal-buffered saline with 2.5% dextrose containing 
0.1% gelatin, 0.5 mM MgCI2, and 0.15 mM CaCI2 (DGVB) ;1 veronal-buffered saline containing 
0.1%  gelatin  and  0.01  M  EDTA  (EDTA-GVB);  and  veronal  buffer  with  2.5%  dextrose 
containing 0.1% gelatin and 0.01  M  EDTA (EDTA-DGVB;  13). 
Complement Components.  Human (hu) Cls (14), C4 (15), C3 (16), C4 binding protein (C4-bp; 
17), C3bINA (18), factor B  (19), and properdin (P; 20) were purified as previously described. 
C2  was  purified  according  to  Nagasawa  et  al.  (21),  except  that  the  final  step  (affinity 
chromatography on Sepharose C4) was omitted. C2 was oxidized as described (22) and referred 
to as °xYC2. C5 was purchased from Cordis Laboratories, Inc., Miami, Fla. Guinea pig (gp) C1 
was partially purified as described in (23). C6-9 was prepared from guinea pig serum (24). 
* Supported by grants AI 08499 and CA 16247 from the National Institutes of Health, Bethesda, Md. 
l Abbreviations used in this paper: B, factor B; °~YC2,  oxidized human C2; C4-bp, C4 binding protein; CR1, 
complement receptor for C3b and C4b (immune adherence receptor);  DGVB, veronal-buffered  saline with 
2.5% dextrose  containing 0.1% gelatin, 0.5  mM  MgCI2, and 0.15  mM CaCI2; EA, sheep  erythrocytes 
sensitized with rabbit IgG antibody; EAC1, EAC14, EAC14°xy2, and EAC14°xY23, cellular intermediates 
prepared with EA and bearing the major cleavage fragments  of the designated complement component; 
EAC 14u~, EAC 142~, EAC 14°xY2~, EAC 14°xY23um, and EAC 14°'Y235n~, cellular intermediates, same as 
above, except that the final components of each were in limiting amounts; EDTA-DGVB, veronal buffer 
with 2.5% dextrose  containing 0.1% gelatin and 0.01 M  EDTA;  EDTA-GVB, veronal-buffered  saline 
containing 0.1% gelatin and 0.01 M  EDTA;  gp,  guinea pig;  hu,  human; NP-40,  Nonidet  P-40;  P, 
properdin; SDS-PAGE, sodium dodecyl sulfate-polyacrylamide  gel electrophoresis; SFU, site-forming  units. 
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Cellular Intermediates.  EAC1,  EAC14,  EAC14°xY2, and  EAC14°xY23 were  prepared  from 
antibody (IgG)-sensitized sheep erythrocytes (EA) by reacting sequentially with 300 site-forming 
units  (SFU) of Clgp, C4hu, ~YC2hu,  and C3hu until  the corresponding stage of each of the 
intermediate  cells  was reached.  EAC14 cells  bearing  1.0-1.5 C4 sites/cell were prepared by 
incubating EA with excess C1 (300 SFU) and limiting amounts of  C4hu. The cells were referred 
to as EAC  14~, EAC 142~, EAC 14°~2~, EAC 14°~23t~, and EAC°~235~,., and were prepared 
in  the  same  manner,  except  that  the  limiting  components  were  the  final  ones  in  each 
intermediate. 
Complement Receptor.  CR 1 was purified by sequential column chromatography on Biorex-70 
(Bio-Rad Laboratories, Richmond, Calif.), Sepharose-lentil lectin, and Sepharose-C3 affinity 
chromatography, according to the method of Fearon (9). During purification, CR 1 was assayed 
by its inhibitory activity for C3 convertase either of the classical (C4b,2a)  or the alternative 
(C3b,Bb,P)  pathway.  Inhibition  of the  alternative  pathway  C3  convertase was  assayed  as 
previously described  (9).  Inhibition  of the classical  pathway C3 convertase was assayed as 
follows:  100 #1 of EAC142r~, 1 ×  10S/ml, was incubated with  100 #1 of samples from fractions 
diluted in DGVB for 15 min at 30°C. Residual C4b,2a activity was developed by adding 1.3 
ml of guinea pig serum diluted  1:50 with EDTA-GVB, followed by incubation at 37°C for 60 
min. The protein concentration of CR1 was estimated by a modified Folin method (25) using 
bovine serum albumin (BSA) as a standard. 
Radiolabeling.  C4 was labeled with x26I by means of Enzymobeads (Bio-Rad Laboratories). 
25 #g of C4 in 25 #1 was incubated with 50 #1 of Enzymobeads, 1 mCi ofl~I (Amersham Corp., 
Arlington Heights,  Ill.),  and  25 /xl of 2% glucose. After incubation  for 20 min  at  0°C,  the 
reaction was stopped by addition of 50 #1 of 0.05% sodium azide. Free iodine was removed by 
dialysis.  The  specific  activity  was  4  X  10  e cpm/1  #g  protein,  a~I-C4b  was  prepared  by 
incubation of 25 #g 1~I-C4 with  1 #g of Cls at 37°C for 2 h. 
CR1 was labeled by the same method used for C4, and separated from the free iodine as 
follows:  the labeled mixture was diluted with 0.1% Nonidet P-40 (NP-40; Particle Data, Inc., 
Elmhurst, Ill.)  and applied to a 0.3-ml Biorex-70 column equilibrated with 0.05 M  phosphate 
buffer, pH 7.2, containing 0.02 M NaCI and 0.1% NP-40. The column was washed extensively 
125  in the starting buffer and  I-CR1 was eluted with 0.5 M  NaC1. The specific activity was 7 × 
104 cpm/1 #g protein. 
Sodium Dodecyl Sulfate-Polyacrylamide Gel Electrophoresis (SDS-PAGE).  This  was  performed 
according to the method of Laemmli (26).  10% running and 5% stacking gels were used. For 
labeled samples, radioautography was carried out by exposing the dried gel to an X-Omat R 
film (XR-5; Eastman Kodak Company, Rochester, N. Y.) at -70°C overnight. For estimation 
of the molecular weight of the bands, the following standards were used: 200,000  myosin (H 
chain); 92,500 phosphorylase B; 68,000 BSA; 43,000 ovalhumin; 25,700 a-chymotrypsinogen; 
and  18,400 ~-lactoglobulin. 
Results 
Purification of an Inhibitor of C4b,2a from Human E~ythrocyte Membranes.  The inhibitory 
factor was isolated from human erythrocytes as described by Fearon  (9), except that 
the membranes originating from 2  X  10  is erythrocytes were washed extensively in a 
Pellicon  Cassette  System  (Millipore  Corp.,  Bedford,  Mass.),  and  concentrated  to a 
volume  of 300  ml  before  solubilization  in  detergent  and  loading  in  a  Biorex-70 
column. The activity of the inhibitor was followed by two assays; that is,  the decay- 
dissociation of C4b,2a and C3b,Bb,P formed on sheep erythrocytes. During all steps 
of purification, the two activities coincided as illustrated in Fig. 1.30/~1 of the purified 
inhibitor at a  concentration of 200 #g/ml gave a  single stained  band in SDS-PAGE 
under reducing or nonreducing conditions, with a  molecular weight close to 200,000. 
Therefore,  a  single  glycoprotein  from human  erythrocyte membranes,  identified  as 
the complement receptor (CR1) of cells (10), inhibits the activity of the C3 convertase 
of both the classical and alternative pathways. 1140  COMPLEMENT  RECEPTOR  INHIBITS COMPLEMENT CASCADE 
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Fio.  1.  Chromatography  on Biorex-70  of extracts of erythrocyte membranes.  2  X  10 'n human 
erythrocytes were washed in phosphate-buffered saline (0.15 M, pH 7.4) and lysed in  18 liters of 
hypotonic buffer (5 mM phosphate,  0.5  mM EDTA). The membranes were washed extensively 
with the same hypotonic buffer containing 0.5  mM phenyl methyl-sulfonyl fluoride, by passage 
through a Pellicon Cassette System and centrifuged at 18,000 g for 1 h. To the collected membranes 
in a volume of about 300 ml, an equal volume of 1% NP-40 in 5 mM phosphate buffer containing 
0.15 M sodium chloride and 0.5 mM EDTA was added and incubated for 3 h in the cold. After 
solubilization, 1,200 ml of 0.05 M phosphate buffer,  pH 7.2, was added to adjust the conductivity 
to 3.8  mS  (0°C)  and  the insoluble fraction was  removed by centrifugation. The supernate was 
loaded in a Biorex-70 column (3 X  15 cm) equilibrated with 0.05 M phosphate buffer containing 
0.1% NP-40 and 0.02 M sodium chloride, pH 7.2, (conductivity 3.8 mS). The column was washed 
with 1 liter of the same buffer and a linear salt gradient was applied. The gradient was formed by 
mixing 400 ml of the starting buffer with 400 ml of this buffer containing 0.35 M sodium chloride. 
The fractions  were assayed as follows: samples  were diluted 1:20 and 100 lal were incubated for 15 
min at 30°(] with equal volumes of EA(] 142u= or EA(]43BP (1 X 108/ml). Then, 1.3 ml of guinea 
pig serum diluted  1:50 with EDTA-GVB or 1:20 with EDTA-DGVB was added to EA(]I42u~ or 
EA(]43BP,  respectively.  The tubes were incubated  at  37°(] for  1 h  and  the degree of lysis was 
measured.  It is clear that the two inhibitory activities were eluted from the column in a parallel 
fashion.  The inset  (middle track)  shows  the results  of the 4.5% SDS-PAGE, under nonreducing 
conditions,  of the final purified (JR 1 obtained after additional steps of purification. Also shown are 
purified/~IH (left track)  and (]4 (right  track). 
Mechanism of Inhibition of the Classical Pathway (33 Convertase.  The inhibitory activity 
of CR1 on C3 consumption  by C4b,2a was directly shown as follows: EAC 14°xY2 cells 
were prepared  with 300 SFU of Clgp,  C4hu,  and °xYC2hu.  Samples  (0.2  ml, 2  ×  l0  T 
cells) were incubated with equal volumes of various dilutions of CR 1 in DGVB  for 30 
min at 30°C. The cells were washed twice by centrifugation, the pellets were incubated 
with 0.2 ml of purified human  C3  (36 SFU)  for 30 rain at 30°C, and the residual  C3 
hemolytic activity was  determined.  The  results  showed  a  dose-dependent  inhibition 
of C3 consumption  by CR1  (Fig. 2). The  effects could be observed at concentrations 
of the receptor <50  ng/ml. 
The experiments  illustrated  in Fig.  3 A  demonstrate  that  this inhibitory activity is 
associated  with  the  decay  of  C4b,2a  sites  from  the  EAC142  cells.  Erythrocyte 
intermediates were prepared with 300 SFU of C 1 and C4, but with limiting amounts 
of C2. The EAC 142~m cells were incubated with equal volumes of various dilutions of 
CR 1 at  30°C  and  the time course of the C4b,2a  decay was studied.  The  half-life of 
the  enzyme  was  considerably  shortened  in  the  presence  of the  receptors  in  a  dose- 
related manner.  For example, at a  concentration  of CR1  of 95 ng/ml,  the half-life of 
the C4b,2a sites was 4.5 rain, whereas in controls incubated  with buffer,  the half-life 
was 8  min.  Stabilized enzyme C4b°~Y2a was also inhibited  (Fig. 3 B). KYOKO  IIDA  AND  VICTOR  NUSSENZWEIG  1141 
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Fro.  2.  Inactivation of C3-convertase activity by CRI. 0.2 ml of EAC14°~2 cells (1 X  10S/ml) was 
incubated with an equal volume of CR1 for 30 min at 30°C and washed twice with DGVB. 0.2 ml 
of purified human C3 was added to each pellet. After 30 min of incubation at 30°C, supernatant 
fluids were separated and the residual C3 hemolytic activities were determined. The amount of C3 
initially available (36 SFU) was calculated from the samples incubated with EAC14. 
1.0 
0 
2.0 
~ 
1.0 
.5 
B 
.1 
lo  2o  30 
Ti m et'min) 
Flo.  3.  Decay of C4b,2a sites from EAC 142 cells prepared with C2 (A), or oxidized C2 (B).  1 ml 
of EAC142tt~ (1 ×  108/ml) or EAC 14°~'2hm was mixed with an equal volume ofpre-warmed DGVB 
(O),  or  with  CRI  at  final concentrations of 24  (&), 48  (1),  95  (A)  and  190  (I--I) ng/ml, and 
incubated at 30°C. At timed intervals, 200#1 samples were withdrawn, and  1.3 ml of guinea pig 
serum diluted 1:50 with EDTA-GVB was added. The mixtures were incubated for 60 min at 37°C 
to develop lysis.  In the experiment using °~C2, samples were washed twice after incubation with 
CRi+ 
Because C4-bp and CR 1 have similar effects on the classical pathway C3 convertase 
(27), we compared their activities and  found that  CR1  was  the superior inhibitor 
(Fig.  4).  On  a  weight  basis,  -5-10  times  less  CR1  than  C4-bp  was  necessary to 
inactivate the same number of C4b,2a sites.  Due to nonspecific aggregation, micelle 
formation, or assembly of polymers, the apparent molecular weight of either protein 
by gel filtration under nondenaturing conditions is -1  X  10  e. 
Because  the  immune  adherence  receptor  hinds  C4b  (11,  12),  the  most  likely 
explanation for the inhibitory activity of CR1 on C4h,2a is that CR1 competes with 
C2  for  a  binding  site  on  C4b.  This  was  investigated  by  radiolabeling  CR1  and 1142  COMPLEMENT  RECEPTOR  INHIBITS  COMPLEMENT  CASCADE 
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Fro.  4.  Dose response curves of inactivation  of C4b,2a by CR 1 and C4-bp.  100 #1 of EAC 14°~2tim 
cells  (1  ×  10S/ml)  was incubated  with  100 #1 of serially diluted  CRI  (A), or C4-bp  (O)  at  30°C. 
After  incubation  for 30 rain, cells were washed  twice with  DGVB,  and then  1.5 ml of guinea  pig 
serum diluted  1:50 with EDTA-GVB was added. The mixtures were incubated for hemolysis for 60 
min at 37°C. The residual C4b,2a sites were then calculated. The number of C4b,2a sites in controls 
consisting  of EAC14°~Y21im cells incubated  with  DGVB  was 0.99.  It is apparent  that  CR1  is more 
effective  than C4-bp in the inactivation  of C4b,2a sites. 
studying its incorporation onto EAC14 in the presence or absence of C2. In preliminary 
experiments,  in  which  various  erythrocyte intermediates  were  incubated  with  12sI- 
radiolabeled  CR1,  we  found  that  a  maximum  of  20%  of  the  counts  could  be 
incorporated on EAC14, whereas only 3% bound EAC 1 (data not shown).  2 Next, we 
studied the inhibitory effects of C2. Samples of EACI4°XY2 cells were prepared with 
serially diluted °xYC2 and incubated with 100 #1 of a~I-CR1  (0.14 #g protein) at 30°C 
for 30 min. After washing, the binding of CR1  to cells was determined.  Fig. 5 shows 
that °~YC2 prevented the binding of I~I-CR1  to cells in a dose-dependent fashion. As 
a control, we found that purified factor B  had no effect on the incorporation of lzsI- 
CR1 on EAC14 cells. 
In all experiments so far described,  the activity of CR1  on C4b,2a was studied on 
erythrocyte intermediates prepared with excess C4 (300 SFU). Under these conditions, 
it might be difficult to detect any direct and irreversible effects of CR1  on C4b. To 
investigate  this possibility,  we  incubated  samples  of EAC14tim  (0.83  sites/cell)  with 
CRI  alone, or with CR1  plus C3b/C4b  inactivator, or with buffer alone for 30 min 
at 30°C and measured the remaining hemolytic activity. As positive controls, other 
samples  of EAC14u~ were incubated with C3b/C4b  inactivator, C4-bp, or mixtures 
of these two proteins. As shown in Fig. 6, CR1 and C4-bp alone did not influence the 
hemolytic activity of EAC14um even at concentrations of 1.5  and  15 #g/ml,  respec- 
tively.  Furthermore,  neither  protein  enhanced  the  enzymatic  activity  of C3b/C4b 
inactivator on the EAC14  cells, s This  is in sharp contrast to the results of previous 
experiments  showing that  at  concentrations  10  times  smaller,  CR1  inactivated  0.8 
C4b,2a sites per EACi42~  cell  (Fig. 4). 
About 43% of the counts bound to EA1423, probably reflecting a higher affinity of CR1  for C3b than 
for C4b. 
a A  previous report  from  our laboratory indicated  that  C4-bp  enhances the cleavage of C4b by C3b/ 
C4b  inactivator  (27).  This  conclusion  was based  mainly  on  the  observation  that  C4-bp  and  C3b/C4b 
inactivator  had  synergistic  inhibitory  effects  on  the  hemolytic  activity  of  EAC142~  (rather  than  on 
EAC14~.,  which  was  used  in  the  present  experiments).  In  light  of  the  results  shown  in  Fig.  4,  the 
pronounced diminution  of C4b,2a sites on EAC142~  treated with C4-bp plus C3b/C4b inactivator, which 
we previously observed, could reflect an increased displacement of C2 by the combined activities of C4-bp 
and enzyme. This would not be without  precedent, because C3b/C4b  inactivator binds stoichiometrically 
to C3b in the presence of~lH  (28). KYOKO  IIDA  AND  VICTOR  NUSSENZWEIG  1143 
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Flo.  5.  Inhibition  of I~I-CRI  binding  to  cells  by increasing  amounts of °rYC2 (O),  or  factor B 
(&). To 200 pl of EAC14 cells (1.5 ×  10S/ml), equal volumes of serially diluted oxidized C2 or factor 
B were added and incubated at 30"C. After 10 min, cells were washed and resuspended in 100/~1 of 
DGVB. To each tube,  I00 #1 of lmI-CR 1 (1 ×  104 cpm) was added. After incubation at 30°C for 30 
min and addition of 1.3 ml of DGVB, the tubes were centrifuged. The cell pellets were washed once 
with DGVB. The percent of counts incorporated onto cells was determined by counting pellets and 
supernatant  fluids.  The  binding  of EACI  was 3.9%  (O).  °~YC2, but  not  factor  B,  inhibited  the 
incorporation of nnI-CR 1, in a dose-dependent  fashion. 
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FIG. 6.  Failure  of CR1  and C4-bp to  enhance  the  inactivation  of the hemolytic activity of 
EAC141~ by C3b/C4b inactivator. Several aliquots of EAC14,m (1 X  10S/ml) bearing 0.83 sites/cell 
were added to 100-/~] mixtures of C3b/C4b inactivator, C4-bp, and CR1, and incubated at 30°C for 
30 rain. Then the cells were washed twice and the residual hemolyticaliy active sites were developed 
by incubation with  300 SFU of C2gp at 30°C  for 20 rain, followed by further  incubation with 
guinea pig serum  diluted  1:50 in EDTA-C;VB. Some of the experiments were performed in the 
absence of C3b/C4b inactivator (top two horizontal lines), or in the presence of | #g/m] (middle 
lines)  or 2/Ig/ml  (bottom lines)  of the enzyme.  The results clearly show, that increasing doses of 
CR]  (C), Z~, El)  or of C4-bp (0,  A, ll)  were without  effect  in the inactivation of the hemolytic 
activity of EAC 14~. 
Taken together, these observations support the idea that CR 1 and C2a compete for 
the same or similar sites on C4b, and that this may be the only basis for the inhibitory 
effects of CR 1 on the classical pathway C3 convertase. 
Inhibition of Classical Pathway (35  Convertase.  The  effect of CR 1 on  the  classical 
pathway  C5  convertase was  investigated  by  measuring  the  hemolytic activity  of 
EAC14°xY231a~ (100 #1, 107 cells) after incubation with serially diluted CR1 for 30 min 
at 30°C. The results are shown in Fig. 7. In the presence of 10 ng/ml of CR1, 50% of 
the available sites of C5 convertase were inhibited; that is, about 0.6 sites/cell. This 1144  COMPLEMENT  RECEPTOR  INHIBITS COMPLEMENT  CASCADE 
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FIG.  7.  Inactivation  of C4b,2a,3b  by  CR1.  100  #1  of EAC14°'~23~  cells  (1  X  108/ml) was 
incubated with 100/xl of serially diluted CRI at 30°C for 30 rain. Then 100/~1 of C5hu was added 
at a dilution calculated to provide 300 SFU/eelI, and the mixture was incubated at 30°C for 6 rain. 
To develop lysis,  1.2  ml of the C6-9 reagent  diluted  1:200 with EDTA-DGVB was  added  and 
incubated for 60 rain at 37°C. The number of C4b,2a,3b  sites available was  1.23, as determined in 
controls incubated in the absence of CR 1. 
Fic.  8.  Cleavage of C4b  by  CR 1 and  C3b/C4b  inactivator.  0.04  #g  of l~I-labeled C4b  was 
incubated with PBS alone (track  1), with 1.4/tg of CR 1 (track  2), with 1.4 #g of CR1 and 0.16 #g 
of C3b/C4b inaetivator (track 3), or with 0.16 #g of C3b/C4b inactivator (track 4) in a total volume 
of 30 #1 at 37°C for 3 h. After reduction with 2-mercaptoethanol, samples  were analyzed by  10% 
SDS-PAGE, followed by radioautography. CR1 functioned as an essential cofactor for the proteolysis 
of C4b by C3b/C4b inactivator. The a' chain of C4b is cleaved into fragments a2, a3, and a4, in 
mixtures containing both CRI and C3b/C4b inactivator, but it is not affected in the presence  of 
either protein alone. 
concentration of CR 1 is three times smaller than that necessary to inactivate the same 
number  of C4b,2a  sites  (Fig.  4).  A  similar experiment  was performed  to examine  the 
effects of CRl  on EAC14°~Y235Um (0.7 sites/cell). In contrast to its inhibitory activities 
on  EAC142tim  and  EACI423nm,  CR1  was  totally  inactive  on  EAC142351im  even  at 
concentrations  of 800  ng/ml  (data  not shown). 
Activity of CRI  on  C4b  in  the Fluid Phase.  The  previous  experiments  demonstrated 
that,  like  C4-bp,  CR1  promotes  the  decay-dissociation  of the  classical  pathway  C3 
convertase.  Fig. 8  shows,  in addition,  that  CR 1 and  C4-bp  have analogous  activities 
on fluid phase C4b, because both function as cofactors for the cleavage of C4b.  In the 
presence  of CR 1  (or C4-bp),  C3b/C4b  inactivator  cleaves the a'  chain  of C4b  into KYOKO  IIDA AND VICTOR  NUSSENZWEIG  1145 
three fragments, a2, a3, and a4, with apparent molecular weights of 44,000, 27,000, 
and 17,000, respectively. By SDS-PAGE, the fragments originating from the cofactor 
activities  of CR1  and  C4-bp  are  indistinguishable.  From  the  results  of several 
experiments, the cofactor activity of C4-bp is between two and four times higher than 
that of CR1 on a weight basis. 
Discussion 
It  has  been  shown  previously  that  CR1  inhibits  the  alternative  pathway  C3 
convertase (C3b,Bb,P)  by enhancing the decay of Bb  (9). The main finding of this 
paper is that CR1  also inhibits the C3 and C5 convertases of the classical pathway 
(C4b,2a and C4b,2a,3b). 
In  purifying functional CR1  to  homogeneity, we  monitored  activity with  two 
assays, i.e., the inhibition of hemolytic function of C4b,2a and C3b,Bb,P assembled 
on the erythrocyte surface. We found throughout the isolation procedure that both 
activities were similarly distributed.  The  final preparations  showed a  single poly- 
peptide chain in either the reduced or unreduced form, with a  molecular weight of 
~200,000 (Fig. 1). At low concentrations, the purified protein inhibited the consump- 
tion of C3 by C4b,2a (Fig. 2). On the basis of these findings, we conclude that CR1 
inhibits the classical pathway C3 convertase, an enzyme whose active site is in C2a, 
but whose function is C4b dependent. 
Other cell-associated decay-accelerating factors of the classical pathway C3 conver- 
tase  have  previously been  described.  Several  years  ago,  Hoffman found  such  an 
activity in crude butanol extracts ofstroma from human red cells (29). More recently, 
Burge et  al  (30) isolated an inhibitor of C4b,2a  from guinea pig erythrocytes. Its 
properties are similar to those of CR1, which suggests that they may be homologous 
proteins. 
The mechanism of inhibition of C4b,2a by CR1 probably consists of competitive 
displacement of C2a from C4b. This is indicated by observations that the purified 
receptor enhances the decay of the hemolytic activity of EAC142  (Fig. 3)  and that 
°xYC2 inhibits the binding of 12SI-CR 1 to EAC 14 cells (Fig. 5). The possibility of direct 
effects of CR 1 on C4b was excluded in experiments showing that CR 1 alone did not 
inhibit the hemolytic activity of EAC 14~, nor did it enhance the inactivation of the 
cell-bound C4b by C3b/C4b inactivator (Fig. 6). 
It is of interest that the overall effects of CR1  and the serum protein C4-bp  on 
EAC14, EAC142, and fluid phase C4b are similar, although quantitative differences 
were  noticed.  Neither  protein  irreversibly  influences  the  hemolytic  function  of 
EAC 14am; both promote decay of EA142, and both serve as cofactors for the cleavage 
of fluid phase C4b.  However, on a  weight basis, CR I  is a  much better inhibitor of 
EAC142  than  C4-bp  (Fig.  4),  although  as  a  cofactor,  C4-bp  is  apparently  more 
efficient (Fig. 8). 
CR1  is  also  a  powerful  inhibitor  of  the  classical  pathway  C5  convertase 
EAC 14°xY23Um. In this complex enzyme, the proteolytic site resides on the C2a subunit 
and C3b provides an essential anchorage site for the substrate C5 (31-34). Although 
we have not further investigated the mechanisms whereby CR 1 inhibits C5 convertase, 
it is likely that CR1  competes with the substrate C5  for a  binding site on the C3b 
subunit of the enzyme. Under the experimental conditions used, an effect of CR1 on 
the other subunits, C4b°XY2a, seems less likely, because these components were present 1146  COMPLEMENT  RECEPTOR  INHIBITS COMPLEMENT CASCADE 
in great excess on the erythrocytes. Moreover, the inhibitory effects on EAC 14°'Y23tt~ 
were  detected  at  concentrations  of  CR1  below  those  necessary  to  inactivate 
EAC14°xY2nm. 
In short, CR1  controls the activity of all amplifying enzymes of the complement 
cascade that are C3b or C4b dependent, presumably by decay-dissociation of C2 (or 
factor B), by inhibiting the C3b-C5b interaction, or by serving as a  cofactor for the 
cleavage of the a' chain of C4b (and C3b) by C3b/C4b inactivator. Therefore, CR 1 
is a  powerful membrane-associated inhibitor of the complement system whose func- 
tional properties encompass those of the plasma proteins C4-bp and fllH (Table I). 
Because CR 1 inhibits C3b,Bb,P, Fearon (9) proposed that the presence of CR 1 on 
cell  membranes  may prevent  inappropriate  self recognition  by complement.  This 
hypothesis was put forward in the context of recent insights into the mechanisms of 
activation  of the  alternative  pathway  (43-45).  According  to  these  ideas,  low  level 
deposition of C3b, through its metastable binding site, occurs continuously in vivo, 
both on autologous cells and on foreign particles. Whether the cascade will proceed 
or not depends on the interaction between C3b and certain cell surface structures not 
yet well characterized. One of these structures, according to Fearon, might be CR1, 
which would bind to C3b already deposited on another site of the membrane and 
prevent the formation of an intrinsic C3 convertase, C3b,Bb. This hypothesis neces- 
sitates  both  fruitful  and  rapid  collisions  between  the  two  membrane-associated 
moieties. 
On the basis of the present  findings, it is our view that CR1  can function  as an 
inhibitor of enzymes extrinsic to the cells bearing the receptor. A well-known function 
of CR 1 is to promote adherence of C3b- and C4b-bearing substrates to phagocytes. 
This interaction, however, could result in a  microenvironment potentially damaging 
to the plasma membrane of the responding cell. Thus, complement-bearing immune 
complexes  or  bacteria,  in  close  proximity  to  the  host  cell,  might  promote  local 
activation and deposition of complement components, with attendant  lethal conse- 
quences for the host cell. Seen in this context, the ability of some phagocytic cells to 
synthesize and secrete several complement components, including C3 and C4, might 
aggravate these effects. 
We therefore wish to propose that CR1 on the surface of cells supplies an increased 
local concentration  of a  strong  inhibitor of complement  activation,  and,  therefore, 
provides cells with a  mechanism for circumventing damage, while at the same time 
TABLE  I 
Comparison of Properties of CR1, C4-bp, and fl l H 
Properties  CRI*  C4-bp:[:  flirt§ 
Inhibition  of hemolytic  C4b,2a  Yes  Yes  No 
activity of particle as-  C4b,2a,3b  Yes  NDI[  Yes 
sociated  C3b,Bb  Yes  No  Yes 
Cofactor  activity for the  C4b  Yes  Yes  No 
cleavage  of fluid phase  C3b  Yes  Yes  Yes 
* Data in this paper and in reference 9. 
:~ Data in references  27, 35-38. 
§ Data in references  35, 39-42. 
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interacting with complement-bearing substrates. The view that complement receptors 
are also complement inhibitors suggests new ideas about their role on the membrane 
of nonphagocytic cells.  For example,  it  raises  the  possibility  that  CR1  protects  B 
lymphocytes from  the  damaging  effects of the  complement  activation  that  might 
occur in their vicinity, after the specific binding of antigen or of antigen-antibody 
complexes to Fc receptors. 
In  summary,  the  present  observations  show  that  complement  receptors  of cell 
membranes are functionally homologous to the plasma proteins fllH and C4-bp, and 
suggest that these receptors or similar structures may provide a selective advantage to 
cells  or organisms  that,  at  some  time during their life history, may come in  close 
contact with antigen-antibody complexes and complement. Of course, further exper- 
iments are necessary to test this hypothesis directly. 
While this paper was being prepared for submission, findings similar to ours were 
brought to our attention (46). 
Summary 
A  glycoprotein from the membrane of human erythrocytes has been identified as 
a receptor for C3b (CR1). It promotes the dissociation of the alternative pathway C3 
convertase C3b,Bb and the cleavage of C3b by C3b/C4b inactivator. We find that 
CR1 also inactivates the C3 and C5 convertases of the classical pathway. 
CRI  inhibits the consumption of C3 by C3 convertase EAC142 and enhances the 
decay of C4b,2a sites. On a  weight basis, CR1  is ~5-10 times more active than C4 
binding protein, a serum inhibitor of C4b,2a. The binding of 12nI-CR1 to EAC14 cells 
is inhibited by C2. Therefore, it is likely that CR 1 and C2 compete for a site on C4b. 
CR 1 inhibited C5 convertase even more effectively, but had no effect on the assembly 
of the late complement components. 
At high concentrations, CR 1 alone has no irreversible effects on cell-bound C4b. In 
the fluid phase, CR 1 can function as a cofactor for the cleavage of the a' chain of C4b 
by C3b/C4b inactivator. 
A  well-known function of CR1  is to promote adherence of microbes or immune 
complexes bearing C3b and C4b to cells. This interaction could result in a  microen- 
vironment  damaging  to  the plasma  membrane of the responding cell because the 
extrinsic C3b and C4b fragments can serve as additional sites of assembly of enzymes 
of the cascade. We therefore wish to propose that CR 1 on the surface of cells supplies 
an increased local concentration of a  strong inhibitor of the amplifying enzymes of 
the  complement  system  and  provides  cells  with  a  mechanism  for  circumventing 
damage when they bind C3b- and C4b-bearing substrates. 
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